# US 2022/0264872 A1 · Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0264872 A1
- Document ID: US20220264872A1
- Status: Published application
- Kind: A1
- Application number: 17/666,528
- Filed: 2022-02-07
- Published: 2022-08-25
- Earliest claimed: 2015-07-29
- Assignees: Indiana University Research and Technology Corporation
- Applicants: Indiana University Research and Technology Corporation
- Inventors: Keith L. March; Meijing Wang
- Web page: https://patentgrep.com/patent/US20220264872A1

## CPC

- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- G01N 33/5088: {of vertebrates}
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides methods and compositions for treating tissue to preserve and/or rescue tissue from ischemic and/or reperfusion injury and methods for assessing ischemic and/or injuries in cardiac tissue. The disclosed compositions comprise at least a portion of mesenchymal stem cell-conditioned medium.

## Claims

### Claim 1

A method of treating tissue comprising:
contacting the tissue with a composition comprising at least a portion of MSC-conditioned medium (MSC-CM) for a treatment period.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tissue is cardiac tissue, liver tissue, kidney tissue, lung tissue, pancreatic tissue, intestine tissue, thymus tissue, skin, cartilage, bone or cornea tissue.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tissue is comprised by an organ and the organ selected from an adult heart, an infant heart and a neonatal heart.

### Claim 4 (depends on 3)

The method of claim 3, wherein the organ is stored ex vivo or excorporeal, or the organ is in situ.

### Claim 5 (depends on 1)

The method of claim 1, wherein the contacting step:
comprises perfusing the tissue with the composition for the treatment period;
occurs before, during, and/or after an ischemic event;
occurs before and/or during reperfusion;
prevents, at least in part, ischemic damage in the tissue; or
prevents, at least in part, reperfusion damage in the tissue.

### Claim 6 (depends on 1)

The method of claim 1, further comprising:
analyzing the transcriptome of the contacted tissue; and
comparing the transcriptome of the contacted tissue to a baseline transcriptome measured in a matched non-ischemic tissue.

### Claim 7 (depends on 6)

The method of claim 6, wherein the analyzing step comprises analysis of one or more of the following genes: Lonrf1, Chd6, Rhobtb1, Wipf3, Raph1, Slc41a3, Per2, Colq, Cldn5, Timp3, Hlf, Per3, Bcl9, Apold1, Cys1, Wee1, Mthfd11, Col5a3, Sorbs1, Spon2, Slc43a3, Clmp, Rbp1, Prickle3, Nfic, Slc6a6, Nxn, Gpcpd1, Tef, Podn, Mmp14, Smco4, Slc39a14, Eif5a2, Tm4sf1, Slc4a8, Polr2a, Best3, Acot1, Xdh, Id1, Usp2, Zbtb16, Sox4, Plcb4, Dusp18, 2210011C24Rik, Scx, Gja5, Plcd3, Arnt1, Hspa1b, Eepd1, Rcan1, Ppp1r3a, Palld, Mylk4, Cobl11, Nppb, Plekho2, Sox7, Cry2, Tmem171, Vamp5, Dpy1913, Dnajb1, Mrp128, Fry, Flt1, Neurl3, Naca, Neb, Bmp4, Hif3a, Npc1, Phf5a, Ccrn41, Lrrc52, Synpo2, Cntfr, Ppfia4, Inhbb, Acot11, Sh2d4a, Ciart, Dctpp1, Cipc, Naa60, Leo1, Rgs16, Sik3, Gm15417, Pik3r1, Gem, Slco5a1, Gng11, Wnk2, Fam107a, Arhgap20, Guk1, Mapk10, Herpud1, Nme3, Zmiz1, Ubap2, Fosl2, Hyal1, Gbp5, Pdcd7, Jun, Hhipl1, Mcf21, Cox6a1, Ptprm, Dvl3, Fam212a, Adh1, Smim20, Vwa1, Tmtc1, Hspa1a, Fxn, Fkbp2, Eda, Cdpf1, Cdc42bpa, Iigp1, Sorbs2, Lzts1, Clic5, Ctnnbip1, Actn1, Fmo2, Midlip1, Paqr6, Tmem37, Atf7ip, Fis1, Foxo3, Adamtsl4, S100a16, Tnf, Ncoa3, Sp2, Gas1, Vstm4, Unc119b, Cry1, Ptpn18, Lmo4, Rasl11a, Pcdh1, Irs1, Myeov2, Adora2a, Rreb1, Phf19, Rem1, Man2a1, Atp10d, Vamp8, Ttpa1, Ucp2, Sertad1, Usp54, Ncor2, Ier2, Dnal4, Bri3 bp, Mbnl2, Prepl, Uqcr11, 2210407C18Rik, Epas1, Gngt2, Thra, Ptk2b, Hint2, Ubr2, Plcg2, Gimap1, Stk35, Ndufb9 and Wnt5b.

### Claim 8 (depends on 7)

The method of claim 7, wherein:
the tissue is suitable for transplantation if expression of one or more of ARNT1, TNF, CLDN5, Col5a3, and Slc41a3 is the same or decreased relative to the baseline transcriptome and/or if expression of one or more of MTHFD1, LONRF1, RHOBTB1, Cycs1, Hhipl1, and FAM107a is the same or increased relative to the baseline transcriptome; or
the tissue is unsuitable for transplantation if expression of one or more of ARNT1, TNF, CLDN5, Col5a3, and Slc41a3 is increased relative to the standard and/or expression of one or more of MTHFD1, LONRF1, RHOBTB1, Cycs1, Hhipl1, and FAM107a is decreased relative to the baseline transcriptome.

### Claim 9 (depends on 6)

The method of claim 6, wherein the analysis of the transcriptome is performed before the contacting step, during the contacting step, and/or after the contacting step.

### Claim 10 (depends on 6)

The method of claim 6, wherein the results of the comparison are used to determine further treatment of the tissue with the composition and/or to identify suitability of the tissue for transplant.

### Claim 11 (depends on 1)

The method of claim 1, wherein the MSC-CM is adipose-derived MSC-CM (Ad-MSC-CM).

### Claim 12 (depends on 1)

The method of claim 1, wherein the MSC-CM is pretreated by exposure to hypoxia and/or TGF-alpha.

### Claim 13 (depends on 1)

The method of claim 1, wherein the treatment period is selected from between about 20 minutes to 96 hours and, about 20 minutes to 6 hours.
